AbbVie says risankizumab in ulcerative colitis shows remission rates of 54.0%-73.1% at week 96
ABBV•AbbVie said risankizumab in ulcerative colitis showed clinical remission rates of 54.0%-73.1% at week 96. Upadacitinib in Crohn's disease showed clinical remission rates of 78.9%-86.6% at week 144.
1. Clinical remission results
AbbVie said risankizumab in ulcerative colitis showed clinical remission rates of 54.0%-73.1% at week 96. It also said upadacitinib in Crohn's disease showed clinical remission rates of 78.9%-86.6% at week 144.
